[Combined treatment of lung carcinoma. Report on a prospective randomized study with radiotherapy and ICRF 159 (1,2-(3,5-dioxopiperazines-lyl)propane) (author's transl)].
In a clinical randomized trial of 40 patients with inoperable lung carcinoma the success of radiotherapy alone (5000 rads) was compared with a combined modality with radiotherapy (5000 rads) and ICRF 159 (250 mg p.d.). There was no difference in survival rates but haematological toxicity (leucocytes, erythrocytes, platelets and haemoglobin) was marked in patients with combined treatment. In patients with oat-cell-carcinoma survival rates seem to be better after combination therapy.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D000328:Adult; D000368:Aged; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*
D003037:Cobalt Radioisotopes; D010879:Piperazines; D011929:Razoxane
Zur Kombinationsbehandlung des Bronchuskarzinoms. Bericht über eine prospektive randomisierte Therapiestudie mit Strahlentherapie und ICRF 159 (1,2-(3,5-Dioxopiperazin-lyl)propane)